{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T10:55:02Z","timestamp":1785927302861,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00277-020-04084-5","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T23:06:41Z","timestamp":1590016001000},"page":"1565-1573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lymphopenia at diagnosis predicts survival of patients with immunodeficiency-associated lymphoproliferative disorders"],"prefix":"10.1007","volume":"99","author":[{"given":"Mizuki","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakatsu","family":"Hishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadakazu","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouhei","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"issue":"20","key":"4084_CR1","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872","volume":"126","author":"D Dierickx","year":"2015","unstructured":"Dierickx D, Tousseyn T, Gheysens O (2015) How i treat posttransplant lymphoproliferative disorders. Blood 126(20):2274\u20132283","journal-title":"Blood"},{"issue":"11","key":"4084_CR2","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","volume":"99","author":"X Mariette","year":"2002","unstructured":"Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J (2002) Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99(11):3909\u20133915","journal-title":"Blood"},{"issue":"12","key":"4084_CR3","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/modpathol.2009.131","volume":"22","author":"RP Hasserjian","year":"2009","unstructured":"Hasserjian RP, Chen S, Perkins SL, de Leval L, Kinney MC, Barry TS, Said J, Lim MS, Finn WG, Medeiros LJ, Harris NL, O'Malley DP (2009) Immunomodulator agent-related lymphoproliferative disorders. Mod Pathol 22(12):1532\u20131540","journal-title":"Mod Pathol"},{"issue":"3","key":"4084_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.1365-2559.1996.d01-425.x","volume":"28","author":"R Chetty","year":"1996","unstructured":"Chetty R, Biddolph SC, Kaklamanis L et al (1996) EBV latent membrane protein (LMP-1) and bcl-2 protein expression in Reed-Sternberg-like cells in post-transplant lymphoproliferative disorders. Histopathology 28(3):257\u2013260","journal-title":"Histopathology"},{"issue":"5","key":"4084_CR5","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood.V97.5.1165","volume":"97","author":"SJC Stevens","year":"2001","unstructured":"Stevens SJC, Verschuuren EAM, Pronk I, van der Bij W, Harmsen MC, The TH, Meijer CJLM, van den Brule AJC, Middeldorp JM (2001) Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 97(5):1165\u20131171","journal-title":"Blood"},{"issue":"9353","key":"4084_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(03)12271-4","volume":"361","author":"JM Timms","year":"2003","unstructured":"Timms JM, Bell A, Flavell JR, Murray PG, Rickinson AB, Traverse-Glehen A, Berger F, Delecluse HJ (2003) Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin\u2019s lymphoma. Lancet 361(9353):217\u2013223","journal-title":"Lancet"},{"issue":"12","key":"4084_CR7","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/ajh.21003","volume":"82","author":"T Miyazaki","year":"2007","unstructured":"Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, Yamazaki E, Sakai R, Tamaru JI, Kishi K, Kanamori H, Higashihara M, Hotta T, Ishigatsubo Y (2007) Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol 82(12):1106\u20131109","journal-title":"Am J Hematol"},{"issue":"3","key":"4084_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","volume":"8","author":"Z Al-Mansour","year":"2013","unstructured":"Al-Mansour Z, Nelson BP, Evens AM (2013) Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep 8(3):173\u2013183","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"4084_CR9","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/ajt.12211","volume":"13","author":"AM Evens","year":"2013","unstructured":"Evens AM, Choquet S, Kroll-Desrosiers AR, Jagadeesh D, Smith SM, Morschhauser F, Leblond V, Roy R, Barton B, Gordon LI, Gandhi MK, Dierickx D, Schiff D, Habermann TM, Trappe R (2013) Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant 13(6):1512\u20131522","journal-title":"Am J Transplant"},{"issue":"6","key":"4084_CR10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ajh.24346","volume":"91","author":"AS Rosenberg","year":"2016","unstructured":"Rosenberg AS, Klein AK, Ruthazer R, Evens AM (2016) Hodgkin lymphoma post-transplant lymphoproliferative disorder: a comparative analysis of clinical characteristics, prognosis, and survival. Am J Hematol 91(6):560\u2013565","journal-title":"Am J Hematol"},{"issue":"5","key":"4084_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/ajt.12196","volume":"13","author":"J Morscio","year":"2013","unstructured":"Morscio J, Dierickx D, Ferreiro JF, Herreman A, van Loo P, Bittoun E, Verhoef G, Matthys P, Cools J, Wlodarska I, de Wolf-Peeters C, Sagaert X, Tousseyn T (2013) Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant 13(5):1305\u20131316","journal-title":"Am J Transplant"},{"issue":"2","key":"4084_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/hon.2280","volume":"35","author":"T Menter","year":"2017","unstructured":"Menter T, Dickenmann M, Juskevicius D, Steiger J, Dirnhofer S, Tzankov A (2017) Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-\u03baB signalling instead of B-cell receptor signalling. Hematol Oncol 35(2):187\u2013197","journal-title":"Hematol Oncol"},{"issue":"1","key":"4084_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/bjh.14633","volume":"178","author":"T Menter","year":"2017","unstructured":"Menter T, Juskevicius D, Alikian M, Steiger J, Dirnhofer S, Tzankov A, Naresh KN (2017) Mutational landscape of B-cell post-transplant lymphoproliferative disorders. Br J Haematol 178(1):48\u201356","journal-title":"Br J Haematol"},{"issue":"4","key":"4084_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/hon.859","volume":"26","author":"E Vakiani","year":"2008","unstructured":"Vakiani E, Basso K, Klein U, Mansukhani MM, Narayan G, Smith PM, Murty VV, Dalla-Favera R, Pasqualucci L, Bhagat G (2008) Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. Hematol Oncol 26(4):199\u2013211","journal-title":"Hematol Oncol"},{"issue":"25","key":"4084_CR15","doi-asserted-by":"publisher","first-page":"37636","DOI":"10.18632\/oncotarget.9400","volume":"7","author":"E Margolskee","year":"2016","unstructured":"Margolskee E, Jobanputra V, Jain P, Chen J, Ganapathi K, Nahum O, Levy B, Morscio J, Murty V, Tousseyn T, Alobeid B, Mansukhani M, Bhagat G (2016) Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. Oncotarget 7(25):37636\u201337648","journal-title":"Oncotarget"},{"issue":"3","key":"4084_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/bjh.15263","volume":"182","author":"CB DeStefano","year":"2018","unstructured":"DeStefano CB, Desai SH, Shenoy AG, Catlett JP (2018) Management of post-transplant lymphoproliferative disorders. Br J Haematol 182(3):330\u2013343","journal-title":"Br J Haematol"},{"issue":"2","key":"4084_CR17","first-page":"322","volume":"34","author":"Y Hoshida","year":"2007","unstructured":"Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, Nakatsuka S, Tamaru J, Iizuka A, Takeuchi T, Aozasa K (2007) Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34(2):322\u2013331","journal-title":"J Rheumatol"},{"issue":"12","key":"4084_CR18","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.bbmt.2015.07.035","volume":"21","author":"L-P Xu","year":"2015","unstructured":"Xu L-P, Zhang C-L, Mo X-D, Zhang XH, Chen H, Han W, Chen YH, Wang Y, Yan CH, Wang JZ, Wang FR, Zhao T, Liu YR, Liu KY, Huang XJ (2015) Epstein-Barr virus\u2013related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. Biol Blood Marrow Transplant 21(12):2185\u20132191","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"4084_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/bjh.13621","volume":"171","author":"F Montanari","year":"2015","unstructured":"Montanari F, Radeski D, Seshan V, Alobeid B, Bhagat G, O\u2019Connor OA (2015) Recursive partitioning analysis of prognostic factors in post-transplant lymphoproliferative disorders (PTLD): a 120 case single institution series. Br J Haematol 171(4):491\u2013500","journal-title":"Br J Haematol"},{"issue":"4","key":"4084_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4291\/wjgp.v6.i4.181","volume":"6","author":"GY Lam","year":"2015","unstructured":"Lam GY (2015) Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: lessons from other inflammatory disorders. World J Gastrointest Pathophysiol 6(4):181","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"6","key":"4084_CR21","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.transproceed.2016.03.045","volume":"48","author":"R Trusson","year":"2016","unstructured":"Trusson R, Serre JE, Szwarc I, Brunot V, Garrigue V, Delmas S, Kanouni T, Cartron G, Mourad G (2016) Treatment response and outcomes in post-transplantation lymphoproliferative disease vs lymphoma in Immunocompetent patients. Transplant Proc 48(6):1927\u20131933","journal-title":"Transplant Proc"},{"issue":"5","key":"4084_CR22","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/art.10933","volume":"48","author":"N Balandraud","year":"2003","unstructured":"Balandraud N, Meynard JB, Auger I, Sovran H, Mugnier B, Reviron D, Roudier J, Roudier C (2003) Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum 48(5):1223\u20131228","journal-title":"Arthritis Rheum"},{"issue":"12","key":"4084_CR23","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1002\/art.22277","volume":"54","author":"E Baecklund","year":"2006","unstructured":"Baecklund E, Backlin C, Iliadou A, Granath F, Ekbom A, Amini RM, Feltelius N, Enblad G, Sundstr\u00f6m C, Klareskog L, Askling J, Rosenquist R (2006) Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum 54(12):3774\u20133781","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4084_CR24","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/j.1349-7006.2010.01517.x","volume":"101","author":"N Niitsu","year":"2010","unstructured":"Niitsu N, Okamoto M, Nakamine H, Hirano M (2010) Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sci 101(5):1309\u20131313","journal-title":"Cancer Sci"},{"issue":"11","key":"4084_CR25","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1097\/TP.0000000000002269","volume":"102","author":"H Zimmermann","year":"2018","unstructured":"Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, D\u00fchrsen U, Reinke P, Verhoef G, Subklewe M, H\u00fcttmann A, Tousseyn T, Bachy E, Hauser IA, Tarella C, van den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, Trappe RU (2018) Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder. Transplantation 102(11):1914\u20131923","journal-title":"Transplantation"},{"issue":"9","key":"4084_CR26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.bbmt.2004.05.008","volume":"10","author":"A Grigg","year":"2004","unstructured":"Grigg A, Ritchie D (2004) Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 10(9):579\u2013590","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"4084_CR27","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/intimm\/dxm057","volume":"19","author":"T Okazaki","year":"2007","unstructured":"Okazaki T, Honjo T (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19(7):813\u2013824","journal-title":"Int Immunol"},{"issue":"1","key":"4084_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","volume":"7","author":"C M\u00e9n\u00e9trier-Caux","year":"2019","unstructured":"M\u00e9n\u00e9trier-Caux C, Ray-Coquard I, Blay J-Y, Caux C (2019) Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? J Immunother Cancer 7(1):85","journal-title":"J Immunother Cancer"},{"issue":"2","key":"4084_CR29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1046\/j.1365-2141.2002.03619.x","volume":"118","author":"RD Baird","year":"2002","unstructured":"Baird RD, Van Zyl-Smit RN, Dilke T, Scott SE, Rassam SMB (2002) Spontaneous remission of low-grade B-cell non-Hodgkin\u2019s lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. Br J Haematol 118(2):567\u2013568","journal-title":"Br J Haematol"},{"issue":"6","key":"4084_CR30","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1200\/JCO.1996.14.6.1943","volume":"14","author":"E Salloum","year":"1996","unstructured":"Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J (1996) Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 14(6):1943\u20131949","journal-title":"J Clin Oncol"},{"issue":"11","key":"4084_CR31","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.3109\/10428194.2015.1022769","volume":"56","author":"Y Inui","year":"2015","unstructured":"Inui Y, Matsuoka H, Yakushijin K, Okamura A, Shimada T, Yano S, Takeuchi M, Ito M, Murayama T, Yamamoto K, Itoh T, Aiba K, Minami H (2015) Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma 56(11):3045\u20133051","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"4084_CR32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","volume":"13","author":"R Trappe","year":"2012","unstructured":"Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leith\u00e4user M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S, German PTLD Study Group, European PTLD Network (2012) Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 13(2):196\u2013206","journal-title":"Lancet Oncol"},{"issue":"3","key":"4084_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/ejh.12904","volume":"99","author":"CB DeStefano","year":"2017","unstructured":"DeStefano CB, Malkovska V, Rafei H et al (2017) DA-EPOCH-R for post-transplant lymphoproliferative disorders. Eur J Haematol 99(3):283\u2013285","journal-title":"Eur J Haematol"},{"issue":"7","key":"4084_CR34","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41375-019-0380-5","volume":"33","author":"K Kataoka","year":"2019","unstructured":"Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronn\u00e9 L, Kogure Y, Sato Y, Nishida K, Gion Y, Shiraishi Y, Tanaka H, Chiba K, Watatani Y, Kakiuchi N, Shiozawa Y, Yoshizato T, Yoshida K, Makishima H, Sanada M, Onozawa M, Teshima T, Yoshiki Y, Ishida T, Suzuki K, Shimada K, Tomita A, Kato M, Ota Y, Izutsu K, Demachi-Okamura A, Akatsuka Y, Miyano S, Yoshino T, Gaulard P, Hermine O, Takeuchi K, Ohshima K, Ogawa S (2019) Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia 33(7):1687\u20131699","journal-title":"Leukemia"},{"issue":"2","key":"4084_CR35","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/10428194.2018.1480767","volume":"60","author":"A Kinch","year":"2019","unstructured":"Kinch A, Sundstr\u00f6m C, Baecklund E, Backlin C, Molin D, Enblad G (2019) Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation. Leuk Lymphoma 60(2):376\u2013384","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"4084_CR36","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1182\/blood-2016-02-698936","volume":"128","author":"H Miyoshi","year":"2016","unstructured":"Miyoshi H, Kiyasu J, Kato T, Yoshida N, Shimono J, Yokoyama S, Taniguchi H, Sasaki Y, Kurita D, Kawamoto K, Kato K, Imaizumi Y, Seto M, Ohshima K (2016) PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia\/lymphoma. Blood 128(10):1374\u20131381","journal-title":"Blood"},{"issue":"1","key":"4084_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12307-018-00219-5","volume":"12","author":"L Marcelis","year":"2019","unstructured":"Marcelis L, Tousseyn T (2019) The tumor microenvironment in post-transplant lymphoproliferative disorders. Cancer Microenviron 12(1):3\u201316","journal-title":"Cancer Microenviron"},{"issue":"1","key":"4084_CR38","first-page":"26","volume":"9","author":"F Ashrafi","year":"2015","unstructured":"Ashrafi F, Shahidi S, Ebrahimi Z, Mortazavi M (2015) Outcome of rapamycin therapy for post-transplant-lymphoproliferative disorder after kidney transplantation: case series. Int J Hematol Stem Cell Res 9(1):26\u201332","journal-title":"Int J Hematol Stem Cell Res"},{"issue":"32","key":"4084_CR39","doi-asserted-by":"publisher","first-page":"33849","DOI":"10.18632\/oncotarget.5292","volume":"6","author":"GM Crane","year":"2015","unstructured":"Crane GM, Powell H, Kostadinov R, Rocafort PT, Rifkin DE, Burger PC, Ambinder RF, Swinnen LJ, Borowitz MJ, Duffield AS (2015) Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget 6(32):33849\u201333866","journal-title":"Oncotarget"},{"issue":"3","key":"4084_CR40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.blre.2003.12.002","volume":"18","author":"DM Burns","year":"2004","unstructured":"Burns DM, Crawford DH (2004) Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. Blood Rev 18(3):193\u2013209","journal-title":"Blood Rev"},{"issue":"16","key":"4084_CR41","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1182\/blood-2014-01-553362","volume":"124","author":"I Ricciardelli","year":"2014","unstructured":"Ricciardelli I, Blundell MP, Brewin J, Thrasher A, Pule M, Amrolia PJ (2014) Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modi fied EBV-specific cytotoxic T cells. Blood 124(16):2514\u20132523","journal-title":"Blood"},{"issue":"23","key":"4084_CR42","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","volume":"116","author":"JN Barker","year":"2010","unstructured":"Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M, Prockop SE, Koehne G, O'Reilly RJ (2010) Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 116(23):5045\u20135049","journal-title":"Blood"},{"issue":"2\u20133","key":"4084_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000072463","volume":"110","author":"CM Bollard","year":"2003","unstructured":"Bollard CM, Savoldo B, Rooney CM, Heslop HE (2003) Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol 110(2\u20133):139\u2013148","journal-title":"Acta Haematol"},{"issue":"9","key":"4084_CR44","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","volume":"9","author":"CM Bollard","year":"2012","unstructured":"Bollard CM, Rooney CM, Heslop HE (2012) T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 9(9):510\u2013519","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04084-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T07:25:30Z","timestamp":1621495530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04084-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4084"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04084-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"assertion":[{"value":"19 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}